本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Outlook Therapeutics, Inc.

0.4014
-0.0117-2.83%
成交量:100.35萬
成交額:42.11萬
市值:3,334.32萬
市盈率:-0.14
高:0.4350
開:0.4000
低:0.4000
收:0.4131
52周最高:3.39
52周最低:0.3801
股本:8,306.72萬
流通股本:6,773.32萬
量比:0.69
換手率:1.48%
股息:- -
股息率:- -
每股收益(TTM):-2.8900
每股收益(LYR):-1.7940
淨資產收益率:-3.65%
總資產收益率:-209.03%
市淨率:-0.86
市盈率(LYR):-0.22

資料載入中...

公司資料

公司名字:
Outlook Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2010
員工人數:
17
公司地址:
111 S. Wood Avenue,Unit #100,Iselin,New Jersey,United States
郵編:
08830
電話:
傳真:
- -
簡介:
Outlook Therapeutics, Inc.於2010年1月5日在新澤西州註冊成立。該公司是一家生物製藥公司,在歐盟或歐盟、英國或英國率先獲得ONS-5010/LYTENAVA(貝伐珠單抗-gamma)眼科製劑上市許可,用於治療濕性年齡相關性黃斑變性,或濕性AMD。

董事

名稱
職位
Faisal G. Sukhtian
Chairman of the Board and Director
Robert Charles Jahr
Chief Executive Officer and Director and President
Lawrence A. Kenyon
Chief Financial Officer and Corporate Secretary and Director and Executive Vice President and Treasurer
Ralph H. Thurman
Lead Independent Director
Andong Huang
Director
Gerd Auffarth
Director
Julia A. Haller
Director
Julian Gangolli
Director
Kurt J. Hilzinger
Director
Yezan Haddadin
Director

股東

名稱
職位
Robert Charles Jahr
Chief Executive Officer and Director and President
Lawrence A. Kenyon
Chief Financial Officer and Corporate Secretary and Director and Executive Vice President and Treasurer